Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3657538 | 0.98 | OPRD1 (0.56) | OPRD1SLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5497606 | 0.91 | OPRD1 (0.55) | OPRD1SLC6A2SLC6A4SLC6A3SOS1 | |
| Propane SCHEMBL27576805 | 0.91 | OPRD1 (0.62) | OPRD1SLC6A2SLC6A4SLC6A3SOS1 | |
| SCHEMBL21381830 | 0.89 | OPRD1 (0.57) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21385215 | 0.89 | OPRD1 (0.57) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382026 | 0.89 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7325604 | 0.89 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382056 | 0.89 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21384835 | 0.89 | OPRD1 (0.57) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13949638 | 0.89 | SLC6A2 (0.55) | OPRD1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1058780-A | Has the active thiazolidine carboxylic acid amides derivative of anti-allergy, their preparation and application | SANKYO CO (JP) | 1992-02-19 | — | — | CN | claimed |
| US-4499274-A | Process for preparation of substituted formamidine and substituted N-iminomethyl piperidine | MCNEILAB, INC. (US) | 1985-02-12 | — | — | US | claimed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-12-26 | — | — | US | disclosed |
| CN-114671802-B | Preparation method of high-purity ebastine | 江苏联环药业股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-4123538-A | (2-Amino-2-oxoethoxy)acetic acid compounds, compositions and methods | MCNEIL LABORATORIES, INCORPORATED (US) | 1978-10-31 | — | — | US | disclosed |
| US-4105849-A | [(Substituted )phenyl]phenylmethyl-1-(dialkylaminoalkyl)piperidines | G. D. SEARLE & CO. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4035372-A | VASODILATORS | G. D. SEARLE & CO. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4032642-A | SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-06-28 | — | — | US | disclosed |
| US-3965257-A | DIPHENYL-4-PIPERIDYL-METHANES | RICHARDSON-MERRELL INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3956296-A | ANTIINFLAMMATORY, SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-05-11 | — | — | US | disclosed |
| US-3946022-A | ANTIHISTAMINES, ANTIALLERGENS, BRONCHODILATORS | RICHARDSON-MERRELL INC. (US) | 1976-03-23 | — | — | US | disclosed |
| US-3941795-A | ANTIHISTAMINE, ANTIALLERGY, BRONCHODILATOR | RICHARDSON-MERRELL INC. (US) | 1976-03-02 | — | — | US | disclosed |
| US-3931197-A | ANTIHISTAMINE, ANTIALLERGY, BRONCHODILATOR | RICHARDSON-MERRELL INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | OPRD1 107/4885SLC18A3 334/4885SIGMAR1 278/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | OPRD1 1261/4885SLC18A3 514/4885SIGMAR1 2962/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | OPRD1 2016/4885SLC18A3 4013/4885SIGMAR1 2597/4885 |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | OPRD1 107/4885SLC18A3 334/4885SIGMAR1 278/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | OPRD1 746/4885SLC18A3 3476/4885SIGMAR1 1634/4885 |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | OPRD1 112/4885SLC18A3 275/4885SIGMAR1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.